Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837392 · ClinicalTrials.gov registry record · NA
Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety
A NA study, sponsored by University of Iowa.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03837392: Completed NA study, sponsored by University of Iowa.
NCT03837392 is a NA study that has completed, run by University of Iowa. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03837392, a NA study, has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This protocol will test the hypothesis that Acceptance and Commitment Therapy (ACT) is effective in reducing anxiety and depressive symptoms during the perinatal and postpartum periods. Participants should expect their participation in the study to last 9-12 months.
Primary Outcome
The IMAS-R provides continuous and diagnostic scores on mood, anxiety, and distress symptoms.
Interventions
- DIAGNOSTIC_TEST Baseline Assessment (18-26 weeks pregnant)
- BEHAVIORAL Online Intervention and Phone Coaching Interventions
- DIAGNOSTIC_TEST Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum
- DIAGNOSTIC_TEST Follow Up Assessments: 8 weeks postpartum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2023-06-30 |
| Phase | NA |
What the finished NCT03837392 record still lists
NCT03837392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Baseline Assessment (18-26 weeks pregnant) is the first listed.
NCT03837392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03837392 about?
NCT03837392 is a clinical study titled "Efficacy of Brief Acceptance and Commitment Therapy (ACT) for Perinatal Anxiety". This protocol will test the hypothesis that Acceptance and Commitment Therapy (ACT) is effective in reducing anxiety and depressive symptoms during the perinatal and postpartum periods. Participants should expect their participation in the study to last 9-12 months.
What is the current status of trial NCT03837392?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-06-01. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03837392?
The interventions under investigation include: Baseline Assessment (18-26 weeks pregnant) (DIAGNOSTIC_TEST), Online Intervention and Phone Coaching Interventions (BEHAVIORAL), Follow Up Assessments: 34-36 weeks pregnant and 4-week postpartum (DIAGNOSTIC_TEST), Follow Up Assessments: 8 weeks postpartum (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03837392?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03837392's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI